Orphan Disease Opportunity Atlas MCP

io.github.rare-disease-atlasPublished by GitHub account rare-disease-atlasv1.6.0Updated Nov 17, 2026

Myelofibrosis (JAK2+ & Autoimmune MF) flagship playbooks + live 7,000-orphan-disease diligence MCP.

The publisher's own server: Red Atlas Api

VerifiedStreamable HTTPWeb executableFinanceKnowledge & MemoryBusiness & Commerce

Overview

AI-generated overview

A remote atlas that helps founders and translational researchers evaluate orphan-disease startup opportunities, funding paths and disease case studies.

What you can do
  • Match orphan-disease startup and translational research blueprints to a founder's background, capital tier and wet-lab needs
  • Retrieve disease case studies covering tractability, standard-of-care gaps, trial catalysts, FDA Orphan Drug economics and open datasets
  • Find non-dilutive funding pathways such as SBIR/STTR, rare-disease foundations, venture philanthropy, FDA Orphan Products and ARPA-H
  • Look up rare-disease patient and clinical validation networks with ethical guidelines for problem discovery
  • Send opt-in feedback or gap reports about missing indications, datasets or citation errors
When to use it
Useful when scoping a rare-disease or orphan-indication venture, comparing founder-fit blueprints, or assembling a non-dilutive funding plan and validation network before committing research effort.
Requirements
Works as a remote streamable HTTP endpoint, or as a local stdio process from a downloadable MCP bundle. No authentication, environment variables or headers are declared.
Before you install
The feedback tool sends content to a third party; it is meant to exclude personal identifiers, patient health records and confidential IP, so review anything submitted. Disease and funding content is reference material, not investment or regulatory advice.

Installation

In SourceWeft

  1. Open Orphan Disease Opportunity Atlas MCP in the dashboard and add it to a workspace.
  2. Enable the server for the chats that should use its tools.

Web executable via Streamable HTTP. Remote servers run from the web runtime once configured in a workspace.

Use with an agent

Paste this prompt into Claude Code, Codex, Cursor or another agent — or into SourceWeft chat. The agent reads this server's install guide, shows you its publisher, endpoint and sign-in, and adds it to your client once you agree. Keys never go into a command.

Read https://sourceweft.com/mcp/io.github.rare-disease-atlas%2Forphan-disease-opportunity-mcp/install.md and connect the MCP server it describes to my client. Before changing any config, show me its publisher, endpoint and sign-in method and wait for my OK. Never put an API key in a command or in a file I would commit; ask me where it should come from.

Read the install guide the agent follows

Other MCP clients

Add this to your client's mcpServers config.

{
  "mcpServers": {
    "orphan-disease-opportunity-atlas": {
      "type": "http",
      "url": "https://api.rare-disease-atlas.workers.dev/mcp"
    }
  }
}

README

orphan-disease-opportunity-mcp (v1.6.0)

[License: MIT] [Data License: CC BY 4.0] [Python 3.10+] [MCP 2026-07-28] [SLSA Provenance] [Live Atlas]

Open Venture & Translational Opportunity Atlas — Read-Only Model Context Protocol (MCP 2026-07-28) Server
Flagship #1: Clonal JAK2 V617F+ Primary Myelofibrosis (jak2-myelofibrosis) • Flagship #2: Reversible Autoimmune Myelofibrosis & Iron/Hepcidin Axis (autoimmune-myelofibrosis) • Web Dossier: https://rare-disease-atlas.github.io

mcp-name: io.github.rare-disease-atlas/orphan-disease-opportunity-mcp

An open, zero-third-party-dependency, 100% read-only Python STDIO + zero-auth Remote Streamable HTTP MCP server (2026-07-28 server/discover + 2025-11-25 initialize + MCP Apps ui://rare-disease-atlas/venture-card) and OpenAPI 3.1 toolkit designed for technical founders (Computational / AI-Bio, Public Health Systems, Venture / Novel Financing) and autonomous AI research agents evaluating high-tractability orphan disease startups, drug-repurposing wedges, 30/60/90-day diligence roadmaps, non-dilutive SBIR/venture-philanthropy grants, and ethical clinical validation guardrails.


Option A: Zero-Install Remote Streamable HTTP MCP (Cloud & Hosted Agents)

Connect immediately over HTTPS with zero local installation and zero API keys:

  • Remote MCP Endpoint (streamable-http): https://api.rare-disease-atlas.workers.dev/mcp
  • A2A Peer Agent Card: https://rare-disease-atlas.github.io/.well-known/agent.json
bash
claude mcp add --transport http orphan-disease-opportunities https://api.rare-disease-atlas.workers.dev/mcp

Option B: Instant 1-Command Local STDIO Execution (uvx or Attested .mcpb)

Run directly from GitHub via uvx with zero external runtime dependencies (pure Python >= 3.10 standard library):

bash
uvx --from git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp orphan-disease-opportunity-mcp

Or download the cryptographically attested orphan-disease-opportunity-mcp.mcpb desktop bundle from GitHub Releases and verify its SLSA build provenance:

bash
gh attestation verify orphan-disease-opportunity-mcp.mcpb --repo rare-disease-atlas/orphan-disease-opportunity-mcp

Add to Claude Code (1 Command)

bash
claude mcp add orphan-disease-opportunities -- uvx --from git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp orphan-disease-opportunity-mcp

Add to Claude Desktop / Cursor / Windsurf / Cline / Antigravity

json
{  "mcpServers": {    "orphan-disease-opportunities": {      "command": "uvx",      "args": [        "--from",        "git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp",        "orphan-disease-opportunity-mcp"      ]    }  }}

Paired Myelofibrosis Flagships (jak2-myelofibrosis & autoimmune-myelofibrosis)

Over 7,000 rare diseases carry FDA Orphan Drug Act structural advantages (7-year US market exclusivity, 100% waiver of the $4,682,003 FY2026 PDUFA filing fee, 25% qualified clinical trial tax credit, and N=120–350 pivotal trials). Our Atlas anchors every tool on a paired positive/negative translational control in human bone marrow fibrosis:

  1. Flagship #1 — Clonal JAK2 V617F+ Primary Myelofibrosis (jak2-myelofibrosis):
    • Single somatic JAK2 V617F mutation in the JH2 pseudokinase domain drives ~50–60% of Primary Myelofibrosis (ORPHA:824, ~15,000–25,000 US patients).
    • All 4 approved Type I JH1 JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) inhibit wild-type JAK2 alongside V617F—causing cytopenias, <15% marrow fibrosis reversal, and 11–23 month median survival post-ruxolitinib failure.
    • High-conviction wedges: mutant-selective JH2 allosteric/PROTAC design (PDB: 6E2Q/8BAK vs 4FVP), Type II persistence breakers, mutant CALR biologics, spatial marrow pathology surrogates, and no-washout RWE trial matching.
  2. Flagship #2 — Reversible Autoimmune Myelofibrosis (autoimmune-myelofibrosis, Nature's Positive Control):
    • JAK2/CALR/MPL-negative lupus/SLE-spectrum marrow fibrosis with dual transfusional + IL-6 -> hepcidin -> ferroportin iron block where human MF-2/MF-3 reticulin fibrosis physically resolves in 74–80% of patients on targeted immunomodulation (Gangat et al., Mayo Clinic 2024).

Exposed Read-Only MCP Capabilities (v1.6.0)

Supports MCP 2026-07-28 (server/discover) and 2025-11-25 (initialize), structured outputSchema + structuredContent, input examples, and MCP Apps UI (ui://rare-disease-atlas/venture-card).

Canonical Read-Only Tools (tools/list & tools/call)

ToolParametersCapability
search_founder_opportunities (alias: match_founder_opportunities)background, capital_tier, wet_lab_required, disease_idSearches startup blueprints anchored on Clonal JAK2+ & Autoimmune Myelofibrosis (plus 4 adjacent cohorts) by founder track, capital tier, and wet-lab requirement.
get_disease_case_studydisease_id (default "jak2-myelofibrosis")Retrieves curated biology, NCT trials, GEO/PDB datasets, failure modes, and FDA Orphan Drug unit economics (jak2-myelofibrosis, autoimmune-myelofibrosis, vexas-syndrome, castleman-disease, systemic-mastocytosis, telomere-biology-disorders).
list_non_dilutive_grants (alias: find_non_dilutive_grants)track (all, sbir-sttr, foundation, venture-philanthropy, regulatory-orphan, federal-translational)Lists NIH/NCI SBIR, MPNRF, LLS TAP, CDCN, ARPA-H, and FDA Orphan grants for Myelofibrosis and rare disease ventures.
get_validation_communitiesdisease_id (default "jak2-myelofibrosis")Retrieves registries, biobanks, patient foundations, and non-extractive research guardrails for Myelofibrosis and rare diseases.
get_90_day_validation_plan (alias: generate_90_day_validation_plan)disease_id, background, capital_tierRetrieves a structured 30/60/90-day diligence roadmap contrasting Clonal JAK2+ vs Autoimmune Myelofibrosis (plus 4 adjacent cohorts).
search_any_orphan_indication (alias: analyze_any_orphan_indication)disease_query, founder_backgroundSearches live OpenTargets, ClinicalTrials.gov v2, and PubMed evidence for any of 7,000+ rare diseases, benchmarked against JAK2+ & Autoimmune Myelofibrosis.

Resources (resources/list & resources/read)

  • briefing://rare-disease-playbook/jak2-myelofibrosis — Clonal JAK2 V617F+ Myelofibrosis playbook (text/markdown)
  • briefing://rare-disease-playbook/autoimmune-myelofibrosis — Reversible Autoimmune Myelofibrosis & iron triage playbook (text/markdown)
  • briefing://rare-disease-playbook/hematology-immunology-expansion — VEXAS, Castleman, Mastocytosis & Telomere cohorts (text/markdown)
  • briefing://rare-disease-playbook/non-dilutive-grants — Non-dilutive SBIR/ARPA-H/MPNRF/LLS TAP grant stack (text/markdown)
  • briefing://rare-disease-playbook/validation-ethics — Registries, biobanks & ethical discovery guardrails (text/markdown)
  • ui://rare-disease-atlas/venture-card — Interactive MCP App HTML card (text/html;profile=mcp-app)

Prompt (prompts/get)

  • evaluate-rare-disease-venture — Read-only 90-day diligence workflow (founder_background, capital_budget, wet_lab_access).

Verification & Quality Assurance

bash
PYTHONDONTWRITEBYTECODE=1 python3 test_mcp.py

License

Source: README.md at commit e90a8b4

Tools

6

search_founder_opportunities

Search Orphan Venture Blueprints

Search startup blueprints anchored on Clonal JAK2+ & Autoimmune Myelofibrosis (plus 4 adjacent cohorts) by track, capital, and wet-lab need.

Parametersbackgrounddisease_idcapital_tierwet_lab_required

get_disease_case_study

Get Myelofibrosis & Orphan Case Study

Retrieve curated biology, NCT trials, GEO/PDB datasets, and failure modes (Flagships: 'jak2-myelofibrosis' and 'autoimmune-myelofibrosis').

Parametersdisease_id

list_non_dilutive_grants

List Non-Dilutive Orphan Grants

List NIH/NCI SBIR, MPNRF, LLS TAP, CDCN, ARPA-H, and FDA Orphan grants for Myelofibrosis and rare disease ventures.

Parameterstrack

get_validation_communities

Get Validation Registries & Guardrails

Retrieve registries, biobanks, patient foundations, and non-extractive research guardrails for Myelofibrosis and rare diseases.

Parametersdisease_id

get_90_day_validation_plan

Get 90-Day Diligence Roadmap

Retrieve a structured 30/60/90-day diligence roadmap contrasting Clonal JAK2+ vs Autoimmune Myelofibrosis (plus 4 adjacent cohorts).

Parametersbackgrounddisease_idcapital_tierwet_lab_required

search_any_orphan_indication

Search Any of 7,000+ Orphan Diseases (Live)

Search live OpenTargets, ClinicalTrials.gov v2, and PubMed evidence for any rare disease, benchmarked against JAK2+ & Autoimmune Myelofibrosis.

Parametersdisease_queryrequiredfounder_background

Version history

2
  1. v1.6.0LatestNov 17, 2026
  2. v1.4.0Nov 15, 2026

Score

100% of the applicable checks met

How complete this listing is, computed from the registry entry, the endpoint and public sources. Not a rating of the server and not a statement that it is safe or working today: reachability is a dated check, and no installs or reviews go into the score.

  • Reached in the last 30 daysRequired25 pts
  • Auth declaredRequired10 pts
  • Tools listedRequired15 pts
  • DescriptionRequired15 pts
  • Logo10 pts
  • Documentation15 pts
  • License10 pts

Other Atlas integrations